External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ESMO GI 2025

July 02 - July 05

Barcelona, Spain / Virtual (Hybrid)

esmo.org

Add to calendar

Medical Materials

Agenda

Coming soon

12:50 PM

Duration 10mins Room Barcelona

TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on-demand TACE alone in patients with systemically untreated, intermediate- to high-burden unresectable hepatocellular carcinoma (uHCC)

Jiahong Dong, Guohong Han, Sadahisa Ogasawara, Ruibao Liu, Shanzhi Gu, Fang Liu, Ming Zhao, Hongtao Hu, Zhaoyu Liu, Kecan Lin, Jingfeng Liu, Zhengyu Lin, Yonghong Zhang, Tao Peng, Jinhua Song, Makoto, Ueno, Jiye Zhu, Lidan Bai, Yanjun Shi, Masatoshi, Kudo

Oncology | Hepatocellular Carcinoma

Add to calendar

01:30 PM

Duration 60mins Barcelona, Spain

MORPHEUS-Liver: A Phase Ib/II, randomised study evaluating tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients (pts) with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)

Richard S. Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng Li, Adam Burgoyne, Ritu Malhotra, Stephen P. Hack, Yulei Wang, Uwe Bader, Janelle Soong, Ed Gane

Oncology | Hepatocellular Carcinoma

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.